Therefore, we first developed a protocol to generate genetically modified neoantigen-augmented iPSC (NA-iPSC) infection by engineered AAV-neoAg, which include 8 neoantigens (CT26), PD1 traps, and PD-L1-targeting microRNAs (Fig. 5a). This evidence concerns the gene CD274 and infection.